TVTX
Travere Therapeutics, Inc.
Latest Form 4:Sale$316KbyLYONS GARY A (Director) · filed Aug 19, 2026
Travere Therapeutics, Inc. (TVTX) has 66 SEC Form 4 filings (157 transaction rows) in the rolling window, disclosed by 11 distinct insiders. Most recent filing: Aug 19, 2026.
The most active filer is Chief Legal Officer and GC REED ELIZABETH E with 12 filings. Insiders have net sold $19.2M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Eric Dube
- Employees:497
- HQ:San Diego, CA, US
- IPO:2012-11-08
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$38.1M
reported sales (SEC code S)
Unique Insiders
11
in the rolling window
Market Cap
$6.2B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
LYONS GARY AFirst in 4 months | Director | Sale | 5,000 | $316K | Aug 19 | SEC ↗ |
LYONS GARY AFirst in 4 months | Director | Sale | 5,000 | $317K | Aug 19 | SEC ↗ |
| Director | Sale | 4,500 | $225K | Jun 16 | SEC ↗ | |
| Director | Sale | 10,000 | $501K | Jun 16 | SEC ↗ | |
Coughlin TimothyFirst in 7 months | Director | Sale | 3,250 | $141K | May 19 | SEC ↗ |
| Director | Sale | 4,500 | $210K | May 7 | SEC ↗ | |
Meckler Jeffrey AFirst filing | Director | Sale | 8,000 | $360K | May 7 | SEC ↗ |
| Chief Research Officer | Sale | 2,763 | $121K | May 7 | SEC ↗ | |
| Chief Legal Officer and GC | Sale | 20,000 | $900K | May 7 | SEC ↗ | |
| Chief Legal Officer and GC | Sale | 2,174 | $101K | May 7 | SEC ↗ | |
| Chief Legal Officer and GC | Sale | 2,076 | $91K | May 7 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 20,000 | $900K | May 7 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 2,174 | $101K | May 7 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 311 | $14K | May 7 | SEC ↗ | |
| CHIEF COMMERCIAL OFFICER | Sale | 2,174 | $101K | May 7 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 22,500 | $989K | May 7 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 2,181 | $102K | May 7 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 310 | $14K | May 7 | SEC ↗ | |
| Director | Sale | 9,750 | $431K | May 4 | SEC ↗ | |
| Chief Research Officer | Sale | 9,100 | $356K | Apr 23 | SEC ↗ | |
| Director | Sale | 32,750 | $1.4M | Apr 16 | SEC ↗ | |
| SVP, CHIEF ACCOUNTING OFFICER | Sale | 21,977 | $903K | Apr 16 | SEC ↗ | |
LYONS GARY AFirst in 4 months | Director | Sale | 8,000 | $329K | Apr 16 | SEC ↗ |
| Chief Legal Officer and GC | Sale | 44,715 | $1.8M | Apr 15 | SEC ↗ | |
| Chief Legal Officer and GC | Sale | 6,785 | $284K | Apr 15 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 64,000 | $2.6M | Apr 15 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 65 | $2K | Apr 15 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 7,248 | $304K | Apr 15 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 1,014 | $43K | Apr 15 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 7,215 | $303K | Apr 15 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 1,018 | $43K | Apr 15 | SEC ↗ | |
| CHIEF COMMERCIAL OFFICER | Sale | 7,215 | $303K | Apr 15 | SEC ↗ | |
Baynes Roy D.First in 5 months | Director | Sale | 10,000 | $330K | Apr 7 | SEC ↗ |
| CHIEF EXECUTIVE OFFICER | Sale | 60,000 | $1.9M | Apr 2 | SEC ↗ | |
| Chief Legal Officer and GC | Sale | 10,000 | $300K | Apr 2 | SEC ↗ | |
| Chief Legal Officer and GC | Sale | 10,000 | $281K | Mar 18 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 60,000 | $1.8M | Feb 24 | SEC ↗ | |
| Chief Legal Officer and GC | Sale | 10,000 | $278K | Feb 19 | SEC ↗ | |
| Chief Legal Officer and GC | Sale | 2,994 | $96K | Feb 5 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 1,745 | $56K | Feb 5 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 1,779 | $57K | Feb 5 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 100,087 | $3.2M | Feb 3 | SEC ↗ | |
| Chief Research Officer | Sale | 12,446 | $409K | Feb 3 | SEC ↗ | |
| SVP, CHIEF ACCOUNTING OFFICER | Sale | 4,333 | $139K | Feb 3 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 7,242 | $233K | Feb 3 | SEC ↗ | |
| Chief Legal Officer and GC | Sale | 7,175 | $230K | Feb 3 | SEC ↗ | |
| CHIEF COMMERCIAL OFFICER | Sale | 7,310 | $235K | Feb 3 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 6,956 | $223K | Feb 3 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 8,135 | $244K | Jan 27 | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 51,865 | $1.6M | Jan 27 | SEC ↗ | |
REED ELIZABETH EFirst in 4 months | Chief Legal Officer and GC | Sale | 10,000 | $273K | Jan 21 | SEC ↗ |
| CHIEF MEDICAL OFFICER | Sale | 2,031 | $82K | Jan 7 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 445 | $17K | Jan 7 | SEC ↗ | |
ROTE WILLIAM E.First filing | Chief Research Officer | Sale | 60,000 | $2.4M | Dec 29 | SEC ↗ |
Inrig JulaFirst filing | CHIEF MEDICAL OFFICER | Sale | 15,000 | $630K | Dec 29 | SEC ↗ |
| SVP, CHIEF ACCOUNTING OFFICER | Sale | 7,402 | $296K | Dec 29 | SEC ↗ | |
| CHIEF COMMERCIAL OFFICER | Sale | 4,980 | $199K | Dec 29 | SEC ↗ | |
| SVP, CHIEF ACCOUNTING OFFICER | Sale | 2,910 | $105K | Dec 16 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 20,000 | $700K | Dec 3 | SEC ↗ | |
Calvin SandraFirst filing | SVP, CHIEF ACCOUNTING OFFICER | Sale | 67,115 | $2.4M | Nov 6 | SEC ↗ |
Coughlin TimothyFirst filing | Director | Sale | 18,000 | $631K | Nov 4 | SEC ↗ |
| CHIEF COMMERCIAL OFFICER | Sale | 5,591 | $196K | Nov 4 | SEC ↗ | |
Dube Eric MFirst filing | CHIEF EXECUTIVE OFFICER | Sale | 92,872 | $2.8M | Oct 30 | SEC ↗ |
Dube Eric MFirst filing | CHIEF EXECUTIVE OFFICER | Sale | 27,128 | $817K | Oct 30 | SEC ↗ |
Heerma PeterFirst filing | CHIEF COMMERCIAL OFFICER | Sale | 2,662 | $80K | Oct 30 | SEC ↗ |
REED ELIZABETH EFirst filing | Chief Legal Officer and GC | Sale | 10,000 | $250K | Sep 24 | SEC ↗ |
Cline Christopher R.First filing | CHIEF FINANCIAL OFFICER | Sale | 454 | $8K | Sep 5 | SEC ↗ |
Cline Christopher R.First filing | CHIEF FINANCIAL OFFICER | Sale | 119 | $2K | Sep 5 | SEC ↗ |
Related companies
Travere Therapeutics, Inc. is in the Healthcare sector.